December 6, 2021. We strongly support the “D” grade reaffirmation of the 2016 recommendation against screening for COPD in asymptomatic adults. There is simply not sufficient evidence that screening for COPD in asymptomatic adults (or treatments for asymptomatic adults) reduce morbidity or mortality or improve health-related quality of life.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR’s Testimony to FDA About Molnupiravir for COVID-19
November 30, 2021: For molnupiravir, the balance of benefits and risks may differ between different types of patients, and not all types of patients were studied.
Read More »GDUFA III Statement of Dr. Diana Zuckerman, President of the National Center for Health Research
November 16, 2021: There are issues of safety and effectiveness in the GDUFA III Commitment letter.
Read More »NCHR’s Comments on USPSTF’s Draft Recommendation Statement on Screening for Eating Disorders
November 15, 2021: We strongly agree with the USPSTF’s “I” grade recommendation that there is insufficient evidence in order to assess the benefits and risks of universal screening for eating disorders in asymptomatic adolescents and adults.
Read More »NCHR Comments on USPSTF’s Draft Recommendation on Aspirin Use to Prevent Cardiovascular Disease
November 8, 2021. Based on the data, we strongly support the “C” grade recommendation for patients 40 to 59 years old with a 10% or more risk of developing CVD, as well as the “D” grade recommendation for patients 60 and older. However, we urge the USPSTF to include additional information to their recommendation.
Read More »